THE UK has secured early access to 90 million coronavirus vaccine doses currently undergoing Phase 2 trials with pharmaceutical companies.
A third of the Covid-19 treatments are being jointly developed by BioNTech and Pfizer – which is the first deal the two firms have signed with any government.
The UK government has signed deals which have secured the country 90 million doses of Covid-19 vaccinations[/caption]
The second deal for 60 million vaccine doses is with Valneva and includes an option to acquire a further 40 million if the vaccine is proved to be safe and effective.
The clinical trials carried out by Valneva, which has a factory in Livingston, Scotland, are expected to be partly funded by the UK government.
It has been reported that the funding will also allow the firm’s Scottish facility to expand allowing production of up to 100 million doses – some of which could be sold around the world.
The Valneva remedy is an “ inactivated virus vaccine”, also known as a “killed vaccine”, which means it consists of virus pathogens which have lost their disease-producing capacity.
Other vaccines use live pathogens which are still alive but are weakened.
Downing Street has penned a third deal with AstraZeneca which gives the UK access to potentially one million doses of a treatment with Covid-19 neutralising antibodies.
This jab could protect those who cannot be vaccinated such as people who with weakened immune systems.
More to follow…
For the latest news on this story keep checking back at Sun Online.
Thesun.co.uk is your go to destination for the best celebrity news, football news, real-life stories, jaw-dropping pictures and must-see video.
Most read in News